• Vivos posted a wider net loss of $1.18 million for the quarter ended March 31, 2026, while operating loss narrowed to $545,492 from $863,532 a year earlier.
• Revenue rose to $36,068, while operating expenses fell to $537,474 from $854,449.
• Non-operating results swung to a loss of $639,353, driven by a $651,628 loss on exchange of warrants.
• Cash totaled $2.53 million at March 31, 2026, with net cash used in operating activities of $429,861.
• RadioGel IDE resubmission was targeted by end of Q1 or in April 2026 after an August 2025 FDA rejection, while manufacturing diversification plans called for one domestic facility at APEL in Richland, Washington and one international site in India to be operational in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023146), on May 14, 2026, and is solely responsible for the information contained therein.